Biolegend, 317347, Ultra-LEAF™ Purified anti-human CD3 Antibody, 5mg

CD3ε is a 20 kD chain of the CD3/T cell receptor (TCR) complex, which is composed of two CD3ε, one CD3γ, one CD3δ, one CD3ζ (CD247), and a T cell receptor (α/β or γ/δ) heterodimer. It is found on all mature T lymphocytes, NK T cells, and some thymocytes. CD3, also known as T3, is a member of the immunoglobulin superfamily that plays a role in antigen recognition, signal transduction, and T cell activation.
5mg
Verified Reactivity: Human
Antibody Type: Monoclonal
Host Species: Mouse
Formulation: 0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.
Endotoxin Level: Less than 0.01 EU/µg of the protein (< 0.001 ng/µg of the protein) as determined by the LAL test.
Preparation: The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
Concentration: The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. Older lots may have also been bottled at 1 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 2.0 µg per million cells in 100 µl volume or 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes: The OKT3 monoclonal antibody reacts with an epitope on the epsilon-subunit within the human CD3 complex.Clone OKT3 can block the binding of clones SK7 and UCHT1.4 The OKT3 antibody is able to induce T cell activation. Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections and activation of T cells. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 317304). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 317326) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Application References(PubMed link indicates BioLegend citation): Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York. Knapp W. 1989. Leucocyte Typing IV. Oxford University Press New York. Barclay N, et al. 1997. The Leucocyte Antigen Facts Book. Academic Press Inc. San Diego. Li B, et al. 2005. Immunology 116:487. Jeong HY, et al. 2008. J. Leuckocyte Biol. 83:755. PubMed Alter G, et al. 2008. J. Virol. 82:9668. PubMed Manevich-Mendelson E, et al. 2009. Blood 114:2344. PubMed Pinto JP, et al. 2010. Immunology. 130:217. PubMed Biggs MJ, et al. 2011. J. R. Soc. Interface. 8:1462. PubMed
Product Citations: Michaels YS, et al. 2022. Sci Adv. 8:eabn5522. PubMed Beck C, et al. 2023. Biomedicines. 11:. PubMed Xiong H, et al. 2023. EBioMedicine. 90:104507. PubMed Anderson W, et al. 2023. Elife. 12:. PubMed Solier S, et al. 2023. Nature. 617:386. PubMed Si W, et al. 2023. iScience. 26:106529. PubMed Issler M, et al. 2023. Methods Mol Biol. 2654:363. PubMed Jiang D, et al. 2023. Nat Commun. 14:3642. PubMed Zheng G, et al. 2021. Signal Transduct Target Ther. 6:236. PubMed Loucif H, et al. 2022. Autophagy. 18:1256. PubMed Glass MC, et al. 2022. Cell Rep. 39:110728. PubMed McMurray JL, et al. 2022. Cell Rep. 39:110858. PubMed Brog RA, et al. 2022. Cancer Immunol Res. 10:962. PubMed Vazquez-Lombardi R, et al. 2022. Immunity. 55:1953. PubMed Zhang Y, et al. 2022. J Immunol Res. 2022:9003902. PubMed Zheng X, et al. 2022. Cells. 12: . PubMed Vidard L, et al. 2023. Immun Inflamm Dis. 11:e749. PubMed Trefny MP, et al. 2023. Nat Commun. 14:86. PubMed Yen M, et al. 2022. Cell. 185:1414. PubMed Yoon HJ, et al. 2022. Exp Mol Med. Online ahead of print. PubMed Mancuso RV, et al. 2020. British Journal of Pharmacology. 177(12):2696-2711.. PubMed Babin L, et al. 2022. Mol Cancer. 21:65. PubMed Rieder SA, et al. 2020. Cell Mol Immunol. . PubMed Hsiue EH, et al. 2021. Science. 371:. PubMed Liu Y, et al. 2021. Immunol Cell Biol. 99:697. PubMed Yuan X, et al. 2022. J Extracell Vesicles. 11:e12235. PubMed Christopher S Garris et al. 2018. Immunity. 49(6):1148-1161 . PubMed Nicolas P, et al. 2022. J Exp Med. 219:. PubMed Yi K, et al. 2022. Front Immunol. 12:802795. PubMed Bak RO, et al. 2018. Nat Protoc. 13:358. PubMed Wang J, et al. 2022. Nat Commun. 13:6866. PubMed Natoli M, et al. 2022. J Immunother Cancer. 10:. PubMed Liu W, et al. 2021. J Biol Chem. 297:101102. PubMed Fang F, et al. 2022. JCI Insight. 7:. PubMed Schofield DJ, et al. 2021. MAbs. 13:1857100. PubMed Chen X, et al. 2021. Theranostics. 11:3392. PubMed Campos Carrascosa L, et al. 2020. J Immunother Cancer. 8:00. PubMed Grandclaudon M, et al. 2019. Cell. 179:432. PubMed Yan B, et al. 2021. Sci Immunol. 6: . PubMed Jung Y, et al. 2021. Nat Commun. 12:3872. PubMed Camviel N, et al. 2022. J Immunother Cancer. 10:. PubMed Warmuth S, et al. 2022. Oncoimmunology. 10:2004661. PubMed Rajamanickam V, et al. 2021. Cancer Immunol Res. 9:602. PubMed Smith CM, et al. 2021. Biochem J. 478:3331. PubMed Saragovi A, et al. 2020. Elife. 9:00. PubMed Glassman CR, et al. 2021. Cell. 184(4):983-999.e24. PubMed Han K, et al. 2021. Nat Metab. 3:318. PubMed Kinloch NN, et al. 2021. Nat Commun. 12:165. PubMed Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed Wen T, et al. 2022. Cancer Immunol Res. 10:162. PubMed Dahal S, et al. 2022. Retrovirology. 19:18. PubMed Collins DR, et al. 2021. Immunity. 54:2372. PubMed Evgin L, et al. 2022. Sci Transl Med. 14:eabn2231. PubMed Ren X, et al. 2022. STAR Protoc. 3:101818. PubMed Pan W, et al. 2020. JCI Insight. 5:00. PubMed Sekine T, et al. 2020. Cell. 183:158. PubMed Sun T, et al. 2019. Haematologica. 105:661. PubMed Sharma V, et al. 2021. ACR Open Rheumatol. 3:277. PubMed Feng Y, et al. 2022. Life (Basel). 12:. PubMed Thakkar D, et al. 2022. J Immunother Cancer. 10:. PubMed Fang F, et al. 2021. Cell Rep. 37:109981. PubMed Correnti CE, et al. 2020. Nat Struct Mol Biol. 27:342. PubMed Xie X, et al. 2021. Front Immunol. 12:625808. PubMed Hurov K, et al. 2021. J Immunother Cancer. 9:. PubMed Si J, et al. 2020. Cancer Cell. 38(4):551-566.e11. PubMed Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed Jiang J, et al. 2021. Front Immunol. 12:785549. PubMed Hu BS, et al. 2020. Cancer Cell Int. 1.189583333. PubMed Wang J, et al. 2019. Sci Rep. 9:8445. PubMed Rousso-Noori L, et al. 2021. Nat Commun. 12:3615. PubMed Winheim E, et al. 2021. PLoS Pathog. 17:e1009742. PubMed Clayton KL, et al. 2021. Cell Host Microbe. 29(3):435-447.e9. PubMed Hu Y, et al. 2016. J Exp Med. 213: 2759 - 2772. PubMed Zhu P, et al. 2022. Cell Commun Signal. 20:121. PubMed Gorchs L, et al. 2022. Cancers (Basel). 14:. PubMed Chen PM, et al. 2022. Sci Adv. 8:eabo4271. PubMed Fujiwara Y, et al. 2021. Nat Commun. 12:5857. PubMed de Haan L, et al. 2021. Int J Mol Sci. 22:. PubMed
RRID: AB_11147370 (BioLegend Cat. No. 317325) AB_11150592 (BioLegend Cat. No. 317326) AB_2571994 (BioLegend Cat. No. 317347) AB_2571995 (BioLegend Cat. No. 317348) AB_2749888 (BioLegend Cat. No. 317349) AB_2749889 (BioLegend Cat. No. 317350)
Structure: Ig superfamily, the subunits CD3γ, CD3δ, CD3ζ (CD247) and TCR (α/β or γ/δ) form the CD3/TCR complex, 20 kD
Distribution: Mature T and NK T cells, thymocyte differentiation
Function: Antigen recognition, signal transduction, T cell activation
Ligand/Receptor: Peptide antigen bound to MHC
Cell Type: NKT cells, T cells, Thymocytes, Tregs
Biology Area: Immunology
Molecular Family: CD Molecules
Antigen References: Barclay N, et al. 1993. The Leucocyte FactsBook. Academic Press. San Diego. Beverly P, et al. 1981. Eur. J. Immunol. 11:329. Lanier L, et al. 1986. J. Immunol. 137:2501.
Gene ID: 916
UniProt: View information about CD3 on UniProt.org
Clone: OKT3
Regulatory Status: RUO
Workshop: HCDM listed
Other Names: T3, CD3ε
Isotype: Mouse IgG2a, κ
Q: Do you guarantee that your antibodies are totally pathogen free?
A: BioLegend does not test for pathogens in-house aside from the GoInVivo™ product line. However, upon request, this can be tested on a custom basis with an outside, independent laboratory.
Q: Does BioLegend test each Ultra-LEAF™ antibody by functional assay?
A: No, BioLegend does not test Ultra-LEAF™ antibodies by functional assays unless otherwise indicated. Due to the possible complexities and variations of uses of biofunctional antibodies in different assays and because of the large product portfolio, BioLegend does not currently perform functional assays as a routine QC for the antibodies. However, we do provide references in which the antibodies were used for functional assays and we do perform QC to verify the specificity and quality of the antibody based on our strict specification criteria.
Q: Does BioLegend test each Ultra-LEAF™ antibody for potential pathogens?
A: No, BioLegend does not test for pathogens in-house unless otherwise indicated.  However, we can recommend an outside vendor to perform this testing as needed.
Q: Have you tested this Ultra-LEAF™ antibody for in vivo or in vitro applications?
A: We don't test our antibodies for in vivo or in vitro applications unless otherwise indicated. Depending on the product, the TDS may describe literature supporting usage of a particular product for bioassay. It may be best to further consult the literature to find clone specific information.